tiprankstipranks
Trending News
More News >
Sundrug Co (JP:9989)
:9989

Sundrug Co (9989) AI Stock Analysis

Compare
0 Followers

Top Page

JP

Sundrug Co

(OTC:9989)

Rating:70Outperform
Price Target:
¥4,927.00
▲(11.42%Upside)
Sundrug Co's strong financial performance, characterized by consistent growth, solid margins, and a stable balance sheet, is the primary driver of its score. While technical analysis indicates a potential bearish trend, the stock's valuation appears reasonable. The absence of significant corporate events or earnings call data did not impact the overall score.

Sundrug Co (9989) vs. iShares MSCI Japan ETF (EWJ)

Sundrug Co Business Overview & Revenue Model

Company DescriptionSundrug Co (9989) is a leading Japanese company operating in the retail and pharmacy sectors. It primarily focuses on the sale of pharmaceuticals, cosmetics, and health-related products through a widespread network of drugstores and pharmacies across Japan. The company is recognized for its commitment to offering a diverse range of high-quality products that cater to the health and wellness needs of its customers.
How the Company Makes MoneySundrug Co generates revenue primarily through its extensive network of retail outlets, which sell pharmaceuticals, cosmetics, and health-related products. The company's key revenue streams include the sale of prescription and over-the-counter medications, personal care items, and beauty products. Additionally, Sundrug Co benefits from its private-label products, which offer higher margins. The company may also engage in strategic partnerships with pharmaceutical companies and suppliers to enhance its product offerings and supply chain efficiency, further contributing to its earnings.

Sundrug Co Financial Statement Overview

Summary
Sundrug Co exhibits strong financial health with consistent revenue growth, solid margins, and a stable balance sheet with low leverage and high equity. The company generates strong cash flows, although there is room for improvement in converting these profits into free cash flow.
Income Statement
85
Very Positive
Sundrug Co has demonstrated consistent revenue growth, with a 6.66% increase in the most recent year. The company maintains healthy profit margins with a gross profit margin of 25.45% and a net profit margin of 3.84% for the latest period. EBIT and EBITDA margins are strong at 5.55% and 7.61% respectively, indicating efficient operational performance. Overall, the income statement reflects a robust financial health with a positive growth trajectory.
Balance Sheet
82
Very Positive
The balance sheet of Sundrug Co is solid, characterized by a low debt-to-equity ratio of 0.14, suggesting minimal leverage risk. The company has a strong equity ratio of 60.73%, indicating a healthy reliance on equity financing. Return on equity stands at 11.40%, highlighting efficient use of equity to generate profits. The company exhibits financial stability with a strong equity base and manageable debt levels.
Cash Flow
78
Positive
Sundrug Co's cash flow statement shows a positive free cash flow growth rate of 160.31% recently, demonstrating effective cash generation capabilities. The operating cash flow to net income ratio stands at 1.34, indicating strong cash generation relative to reported profits. The free cash flow to net income ratio of 0.25 suggests room for improvement in converting profits into free cash flow. Overall, the cash flow position is strong, with excellent cash generation and growth.
Breakdown
TTMMar 2025Mar 2024Mar 2023Mar 2022Mar 2021
Income StatementTotal Revenue
789.40B801.81B751.78B690.46B648.73B634.31B
Gross Profit
200.25B204.09B189.32B171.95B156.51B158.55B
EBIT
42.60B44.50B41.00B37.45B34.05B37.34B
EBITDA
54.42B61.02B56.53B49.52B44.26B46.01B
Net Income Common Stockholders
30.18B30.75B29.13B25.70B23.85B25.33B
Balance SheetCash, Cash Equivalents and Short-Term Investments
67.25B64.96B69.70B80.87B89.33B86.50B
Total Assets
376.60B444.01B420.21B360.67B325.77B308.53B
Total Debt
2.53B38.67B35.00B939.00M529.00M114.00M
Net Debt
-64.72B-26.29B-34.70B-79.93B-88.80B-86.38B
Total Liabilities
129.88B174.29B167.12B124.34B105.18B103.37B
Stockholders Equity
246.72B269.71B253.09B236.33B220.59B205.16B
Cash FlowFree Cash Flow
571.00M7.71B2.96B11.27B11.89B15.29B
Operating Cash Flow
8.89B41.16B41.19B37.38B31.68B31.76B
Investing Cash Flow
-26.57B-35.37B-74.85B-28.51B-20.66B-17.90B
Financing Cash Flow
14.12B-10.60B22.49B-17.33B-8.19B-8.06B

Sundrug Co Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price4422.00
Price Trends
50DMA
4530.40
Negative
100DMA
4318.09
Positive
200DMA
4105.79
Positive
Market Momentum
MACD
-44.50
Positive
RSI
37.53
Neutral
STOCH
22.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:9989, the sentiment is Neutral. The current price of 4422 is below the 20-day moving average (MA) of 4505.55, below the 50-day MA of 4530.40, and above the 200-day MA of 4105.79, indicating a neutral trend. The MACD of -44.50 indicates Positive momentum. The RSI at 37.53 is Neutral, neither overbought nor oversold. The STOCH value of 22.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:9989.

Sundrug Co Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
¥368.26B19.29
0.40%13.86%98.99%
74
Outperform
$594.26B22.2110.45%1.03%17.94%18.31%
74
Outperform
¥534.57B35.49
1.40%5.56%-43.50%
71
Outperform
$554.48B25.414.93%3.26%4.63%-47.30%
70
Outperform
¥513.18B16.6911.61%2.82%6.66%5.56%
70
Neutral
¥701.67B23.73
0.74%6.96%-3.96%
54
Neutral
$5.37B3.35-45.10%2.79%16.77%-0.01%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:9989
Sundrug Co
4,389.00
625.09
16.61%
JP:3141
Welcia Holdings Co., Ltd.
2,543.00
464.00
22.32%
JP:3349
COSMOS Pharmaceutical Corporation
8,815.00
2,379.96
36.98%
JP:3549
KUSURI NO AOKI HOLDINGS CO.,LTD.
3,495.00
395.82
12.77%
JP:7649
Sugi Holdings Co
3,122.00
740.39
31.09%
JP:3391
TSURUHA Holdings
11,270.00
2,440.10
27.63%

Sundrug Co Corporate Events

Sundrug Co. Reports Strong Financial Performance for FY 2025
May 15, 2025

Sundrug Co., Ltd. reported its consolidated financial results for the fiscal year ending March 31, 2025, showing a notable increase in net sales and profits compared to the previous year. The company experienced a 6.7% rise in net sales, reaching 801,811 million yen, and a 5.6% increase in profit attributable to owners of the parent, totaling 30,750 million yen. The financial results indicate a strong performance, with improvements in operating and ordinary profits, reflecting the company’s robust market positioning and operational efficiency. The company also announced an increase in annual dividends, demonstrating its commitment to returning value to shareholders.

The most recent analyst rating on (JP:9989) stock is a Buy with a Yen4100.00 price target. To see the full list of analyst forecasts on Sundrug Co stock, see the JP:9989 Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.